EMERYVILLE, Calif., Jan. 6, 2025
/PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX),
a clinical-stage biopharmaceutical company focused on developing
cell therapies for patients with autoimmune diseases, announced
that the Company will participate at the 43rd Annual J.P. Morgan
Healthcare Conference. Warner
Biddle, Chief Executive Officer of Kyverna, will present its
2025 strategic priorities and key milestones during a
presentation on Monday, January 13,
2025, at 5:15 p.m. PST.
A live audio webcast of the presentation may be accessed via the
Investors section of the Kyverna website at
https://ir.kyvernatx.com/. A replay of the webcast will be
available on the website for 30 days following the
conference.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a patient-centered,
clinical-stage biopharmaceutical company focused on developing cell
therapies for patients suffering from autoimmune diseases. Our
lead CAR T-cell therapy candidate, KYV-101, is advancing through
clinical development with sponsored clinical trials across two
broad areas of autoimmune disease: rheumatology and neurology,
including Phase 2 trials for stiff-person syndrome, multiple
sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic
sclerosis, and two ongoing multi-center Phase 1/2 trials in
the United States and Germany for patients with lupus
nephritis. Kyverna's pipeline includes next-generation CAR
T-cell therapies in both autologous and allogeneic formats with
properties intended to be well suited for use in B cell-driven
autoimmune diseases.
For more information, please
visit https://kyvernatx.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans
and prospects, as well as any other statements regarding matters
that are not historical facts, may constitute "forward-looking
statements." The words, without limitation, "anticipate,"
"believe," "continue," "could," "estimate," "expect," "intend,"
"may," "plan," "potential," "predict," "project," "should,"
"target," "will," "would" and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these or similar identifying
words. Forward-looking statements in this press release include,
without limitation, those related to: Kyverna's participation at
the 43rd Annual J.P. Morgan Healthcare Conference and the
expected discussion of Kyverna's strategic priorities and key
anticipated milestones and Kyverna's ongoing clinical trials.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including: uncertainties related to market conditions, and
other factors discussed in the "Risk Factors" section of Kyverna's
most recent Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q that Kyverna has filed or may subsequently file with the
U.S. Securities and Exchange Commission. Any forward-looking
statements contained in this press release are based on the current
expectations of Kyverna's management team and speak only as of the
date hereof, and Kyverna specifically disclaims any obligation to
update any forward-looking statement, whether as a result of new
information, future events or otherwise.
Contact:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kyverna-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-302343449.html
SOURCE Kyverna Therapeutics